Dihexa — Dosing & Research | Peptide Chats
Research information only. Not medical advice. 18+ only. Not FDA-approved for human therapeutic use.

Dihexa

Also known as: N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, N-hexanoic-tyrosine-isoleucine-(6) aminohexanoic amide, PNB-0408

Peptidomimetic / Angiotensin IV analog / HGF/c-Met receptor system activator

Research chemicalLast updated: October 19, 2026Based on 7 peer-reviewed studiesPreclinical data only — no human trials

What it is

Dihexa is a synthetic compound studied in animals for its effects on memory, cognitive decline, and neurodegenerative diseases including Alzheimer's and Parkinson's. It is thought to work by activating pathways that support the growth of connections between neurons. Not FDA-approved; no human clinical trials completed; evidence is from animal models only.

The scientific side

Dihexa is a metabolically stabilized, orally bioavailable peptidomimetic derived from the N-terminal tripeptide (Nle-Tyr-Ile) of norleucine1-angiotensin IV, an analog of the endogenous hexapeptide angiotensin IV (AngIV: VYIHPF). Earlier AngIV analogs with procognitive properties were limited by rapid metabolic degradation and poor blood-brain barrier (BBB) permeability; Dihexa was chemically engineered to overcome both barriers, yielding an orally active compound that crosses the BBB (PMID 23055539, PMID 25455861). The primary mechanism is activation of the hepatocyte growth factor (HGF) / c-Met receptor system in the central nervous system. Dihexa binds with high affinity to HGF and potentiates its activation of the c-Met receptor. This HGF/c-Met signaling drives synaptogenesis, neurogenesis, and neuroprotection; synaptogenic effects were abolished by the selective c-Met inhibitor PHA-665752, confirming mechanism-dependence. Downstream, c-Met receptor activation stimulates mitogenesis, morphogenesis, stem cell differentiation, and neurogenesis across multiple cell types. In APP/PS1 Alzheimer's model mice, Dihexa additionally activates the PI3K/AKT signaling pathway. A 2018 systematic review of 32 animal studies confirmed that AngIV and its analogs — the class that includes Dihexa — produce consistent procognitive effects across rodent models of memory and learning, with efficacy seen in both normal animals and models of cognitive impairment. As of the reviewed literature, all mechanistic and efficacy data are preclinical; no human pharmacokinetic, pharmacodynamic, or efficacy data have been published.

Class: Peptidomimetic / Angiotensin IV analog / HGF/c-Met receptor system activator

Administration & storage

Storage
No storage data described in reviewed abstracts.
Cautions
No human safety data exists in reviewed literature; all safety assessment is from rodent studies only.,No adverse event data reported in reviewed animal study abstracts; absence of reported events in preclinical studies does not establish human safety.,Compound has not undergone Phase I human safety evaluation in any published study as of reviewed literature.

Legal & regulatory status

US FDA

Not approved by the US FDA for any therapeutic indication. No completed human clinical trials reported in reviewed literature. Remains a preclinical research compound as of 2025.

WADA

Not stated in reviewed literature — requires manual verification. No evidence of inclusion on current prohibited list found in reviewed abstracts.

Health Canada

Not stated in reviewed literature — requires manual verification